Your browser doesn't support javascript.
Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine.
Payne, Rebecca P; Longet, Stephanie; Austin, James A; Skelly, Donal T; Dejnirattisai, Wanwisa; Adele, Sandra; Meardon, Naomi; Faustini, Sian; Al-Taei, Saly; Moore, Shona C; Tipton, Tom; Hering, Luisa M; Angyal, Adrienn; Brown, Rebecca; Nicols, Alexander R; Gillson, Natalie; Dobson, Susan L; Amini, Ali; Supasa, Piyada; Cross, Andrew; Bridges-Webb, Alice; Reyes, Laura Silva; Linder, Aline; Sandhar, Gurjinder; Kilby, Jonathan A; Tyerman, Jessica K; Altmann, Thomas; Hornsby, Hailey; Whitham, Rachel; Phillips, Eloise; Malone, Tom; Hargreaves, Alexander; Shields, Adrian; Saei, Ayoub; Foulkes, Sarah; Stafford, Lizzie; Johnson, Sile; Wootton, Daniel G; Conlon, Christopher P; Jeffery, Katie; Matthews, Philippa C; Frater, John; Deeks, Alexandra S; Pollard, Andrew J; Brown, Anthony; Rowland-Jones, Sarah L; Mongkolsapaya, Juthathip; Barnes, Eleanor; Hopkins, Susan; Hall, Victoria.
  • Payne RP; Translational and Clinical Research Institute Immunity and Inflammation Theme, Newcastle University, Newcastle, UK. Electronic address: rebecca.payne2@newcastle.ac.uk.
  • Longet S; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Austin JA; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.
  • Skelly DT; Peter Medawar Building for Pathogen Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK.
  • Dejnirattisai W; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Adele S; Peter Medawar Building for Pathogen Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
  • Meardon N; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • Faustini S; Institute of Immunology and Immunotherapy, College of Medical and Dental Science, University of Birmingham, Birmingham, UK.
  • Al-Taei S; Institute of Immunology and Immunotherapy, College of Medical and Dental Science, University of Birmingham, Birmingham, UK.
  • Moore SC; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.
  • Tipton T; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Hering LM; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.
  • Angyal A; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
  • Brown R; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
  • Nicols AR; Translational and Clinical Research Institute Immunity and Inflammation Theme, Newcastle University, Newcastle, UK.
  • Gillson N; Public Health England, Colindale, London, UK.
  • Dobson SL; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.
  • Amini A; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Translational Gastroenterology Unit, University of Oxford, Oxford, UK.
  • Supasa P; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Cross A; Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
  • Bridges-Webb A; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Reyes LS; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Linder A; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Sandhar G; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
  • Kilby JA; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
  • Tyerman JK; Translational and Clinical Research Institute Immunity and Inflammation Theme, Newcastle University, Newcastle, UK.
  • Altmann T; Translational and Clinical Research Institute Immunity and Inflammation Theme, Newcastle University, Newcastle, UK; Great North Children's Hospital, Newcastle, UK.
  • Hornsby H; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
  • Whitham R; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • Phillips E; Peter Medawar Building for Pathogen Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
  • Malone T; Peter Medawar Building for Pathogen Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
  • Hargreaves A; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Shields A; Institute of Immunology and Immunotherapy, College of Medical and Dental Science, University of Birmingham, Birmingham, UK; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Saei A; Public Health England, Colindale, London, UK.
  • Foulkes S; Public Health England, Colindale, London, UK.
  • Stafford L; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Johnson S; Peter Medawar Building for Pathogen Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Oxford University Medical School, Medical Sciences Division, University of Oxford, Oxford, UK.
  • Wootton DG; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK; Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK; Institute of Infection, Veterinary and Ecological Sciences
  • Conlon CP; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Oxford Centre For Global Health Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
  • Jeffery K; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Matthews PC; Peter Medawar Building for Pathogen Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Frater J; Peter Medawar Building for Pathogen Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Deeks AS; Peter Medawar Building for Pathogen Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Pollard AJ; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
  • Brown A; Peter Medawar Building for Pathogen Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
  • Rowland-Jones SL; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
  • Mongkolsapaya J; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Siriraj Center of Research Excellence in Dengue & Emerging Pathogens, Faculty of Medicine Sir
  • Barnes E; Peter Medawar Building for Pathogen Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Translational Gastroenterology Unit, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Unive
  • Hopkins S; Public Health England, Colindale, London, UK; Faculty of Medicine, Department of Infectious Disease, Imperial College London, London, UK; NIHR Health Protection Research Unit in Healthcare Associated Infection and Antimicrobial Resistance, University of Oxford, Oxford, UK.
  • Hall V; Public Health England, Colindale, London, UK; NIHR Health Protection Research Unit in Healthcare Associated Infection and Antimicrobial Resistance, University of Oxford, Oxford, UK.
Cell ; 184(23): 5699-5714.e11, 2021 11 11.
Article in English | MEDLINE | ID: covidwho-1466093
ABSTRACT
Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was introduced in the United Kingdom to accelerate population coverage with a single dose. At this time, trial data were lacking, and we addressed this in a study of United Kingdom healthcare workers. The first vaccine dose induced protection from infection from the circulating alpha (B.1.1.7) variant over several weeks. In a substudy of 589 individuals, we show that this single dose induces severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody (NAb) responses and a sustained B and T cell response to the spike protein. NAb levels were higher after the extended dosing interval (6-14 weeks) compared with the conventional 3- to 4-week regimen, accompanied by enrichment of CD4+ T cells expressing interleukin-2 (IL-2). Prior SARS-CoV-2 infection amplified and accelerated the response. These data on dynamic cellular and humoral responses indicate that extension of the dosing interval is an effective immunogenic protocol.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Synthetic / COVID-19 Vaccines Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Cell Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Synthetic / COVID-19 Vaccines Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Cell Year: 2021 Document Type: Article